FBIOX - Fidelity Select Biotechnology

Nasdaq - Nasdaq Delayed Price. Currency in USD
23.20
-0.09 (-0.39%)
As of 8:00PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close23.29
YTD Return10.49%
Expense Ratio (net)0.73%
CategoryHealth
Last Cap Gain0.00
Morningstar Rating★★★★★
Morningstar Risk RatingHigh
Sustainability Rating
Net Assets8.75B
Beta (3y)1.66
Yield0.00%
5y Average ReturnN/A
Holdings Turnover26.00%
Last Dividend0.00
Average for CategoryN/A
Inception DateDec 16, 1985
  • 5 Best Low-Carbon Mutual Funds Focused on Clean Energy
    Zacks3 months ago

    5 Best Low-Carbon Mutual Funds Focused on Clean Energy

    Low carbon mutual funds possess low carbon risk courtesy of investment in low or no fossil fuel stocks

  • 5 Healthcare Mutual Funds to Buy in 2018
    Zacks7 months ago

    5 Healthcare Mutual Funds to Buy in 2018

    Broadly encouraging economic conditions, favorable tax policies and a higher number of approvals from the FDA makes healthcare mutual funds a hotbed of money

  • Biotech Poised for Growth: 3 Healthy Fund Choices
    Zacks9 months ago

    Biotech Poised for Growth: 3 Healthy Fund Choices

    The decline in biotech stocks is momentary and we expect the industry to bounce back in the coming days. So consider investing in these three biotech mutual funds.

  • The 7 Best Growth Funds to Beat the Market in 2018
    InvestorPlace9 months ago

    The 7 Best Growth Funds to Beat the Market in 2018

    The fundamental performance goal for most investors is to outperform the S&P 500 Index, and a smart way to do this is with the best growth funds. As the common investment disclaimer reminds us, past performance is no guarantee of future results. But there’s also truth in the famous Mark Twain quote: “History doesn’t repeat itself but it often rhymes.”

  • 5 Best-Performing Healthcare Mutual Funds in Q3
    Zacks9 months ago

    5 Best-Performing Healthcare Mutual Funds in Q3

    Broadly encouraging economic conditions, favorable policies and a higher number of approvals from the FDA makes healthcare mutual funds a hotbed of money.